Miao Liang

Miao Liang

Auto-generated profile, based on publicly available information

Miao Liang

Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2026 in Journal of Innovative Optical Health Sciences
Verified
Journal Article
Open access
HGHongjie Guan
Hongjie Guan
RGRuyi Guan
Ruyi Guan
MLMiao Liang
Miao Liang
JZJian Zhang
Jian Zhang
XLXiawen Liu
Xiawen Liu
QWQian Wang
Qian Wang
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by ovarian dysfunction and hyperandrogenism. Research into its dynamic pathological mechanisms is limited by the invasive nature of conventional histological methods, which preclude monitoring in live models. The zebrafish has emerged as a valuable model for PCOS due to its physiological similarities to humans. This study explores the application of spectral-domain optical coherence tomography (SD-OCT) as a high-resolution imaging tool for the assessment of PCOS progression and treatment in zebrafish. A testosterone-induced PCOS model was established in adult female zebrafish. The therapeutic efficacy of two doses of Metformin was evaluated. The core methodology involved in vivo SD-OCT imaging of ovarian follicles at multiple time points over 72[ ]h. These morphological changes observed via SD-OCT were consistently corroborated by histology. Metformin treatment, particularly at the high dose (100[ ]mg/L), demonstrated a pronounced therapeutic effect, effectively reversing the testosterone-induced follicular arrest and normalizing ovarian testosterone levels and gonadosomatic index (GSI). This study validates SD-OCT as a powerful and reliable modality for non-invasive monitoring of PCOS in a live zebrafish model.

13 November 2026 in Science Advances
Verified
Journal Article
Open access
XLXiawen Liu
Xiawen Liu
XZXiufen Zheng
Xiufen Zheng
LMLei Ma
Lei Ma
ZYZiqing Yao
Ziqing Yao
XZXuehua Zheng
Xuehua Zheng
WYWei Yi
Wei Yi
Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.